HERON THERAPEUTICS INC (HRTX)
US4277461020 - Common Stock
Commit To Purchase Heron Therapeutics At $2, Earn 17% Annualized Using Options
Heron Therapeutics to Host Investor Day on May 15, 2024 in New York City
/PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company, today announced that it will host an Investor Day on...
Commit To Buy Heron Therapeutics At $2, Earn 22.4% Annualized Using Options
Heron Therapeutics Announces Presentation at the 23rd Annual Needham Virtual Healthcare Conference
/PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company, today announced that Craig Collard, Chief Executive Officer...
Heron Therapeutics Announces Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Corporate Updates
/PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced financial results...
Heron Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results On Tuesday, March 12, 2024
/PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company, today announced that the company will host a conference call...
Heron Therapeutics rises on securing label expansion for pain therapy (NASDAQ:HRTX)
Heron Therapeutics' shares surge on FDA approval of Zynrelef indication expansion for postoperative pain management solution, boosting prospects for the...
Heron Therapeutics Announces FDA Approval of ZYNRELEF® Indication Expansion to Include Additional Orthopedic and Soft Tissue Procedures
/PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company, today announced that the U.S. Food and Drug Administration...
The 3 Most Undervalued Biotech Stocks to Buy in January
These are a number of undervalued biotech companies that investor should possibly look to add to their portfolios.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
It's time to start the week with a breakdown of the biggest pre-market stock movers worth keeping an eye on for Monday morning!
Heron stock gains on sales deal for pain therapy Zynrelef
Heron Therapeutics (HRTX) stock surges 16% as it partners with CrossLink Life Sciences to expand sales network for its pain therapy Zynrelef. Read more here.
Heron Therapeutics Announces Partnership with CrossLink Life Sciences to Expand Promotional Effort for ZYNRELEF®, the First and Only Non-Opioid Dual Acting Local Anesthetic for Post-Operative Pain
/PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company, today announced that it has entered into a five-year...
Commit To Purchase Heron Therapeutics At $1, Earn 41.5% Annualized Using Options
Top Buys by Top Brass: Chief Executive Officer Collard's $138K Bet on HRTX
Penny Stock Powerhouses: 7 Picks Poised for Explosive Growth
Although growth penny stocks present extraordinary risks, if you exercise meticulous care, these ideas might be worth a shot.
Bargain Hunters Take Note: Insider Cluster-Buying At HRTX
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
It's time to dive into the biggest pre-market stock movers as we check out all of the hottest news worth reading about on Wednesday!
Heron Therapeutics Announces Third Quarter 2023 Financial Results and Updates Financial Guidance
Heron is increasing full-year 2023 Net Product Sales guidance for the oncology care franchise to a range of $104 million to $106 million from a prior range of...